GSK 1940029
Alternative Names: 1940029; GSK1940029Latest Information Update: 18 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiacnes
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acne-vulgaris in Austria (Topical, Gel)
- 01 Apr 2015 GlaxoSmithKline completes a phase I trial in Acne vulgaris in Australia (NCT01984801)
- 01 Feb 2015 GlaxoSmithKline completes a phase I trial in Acne vulgaris (In volunteers) in Australia (NCT01938482)